{
    "title": "Bioactivity Descriptors for Uncharacterized Chemical Compounds",
    "authors": "M. Bertoni, M. Duran-Frigola, P. Badia-i-Mompel, E. Pauls, M. Orozco-Ruiz, O. Guitart-Pla, V. Alcalde, V. M. Diaz, A. Berenguer-Llergo, I. Brun-Heath, N. Villegas, A. Garc\u00eda de Herreros, P. Aloy",
    "journal": "Nature Communications",
    "year": 2021,
    "suggested_slug": "bioactivity-descriptors-chem-compounds",
    "suggested_computational_title": "Inference of Bioactivity Signatures via Deep Neural Networks",
    "tldr": "A collection of deep neural networks was developed to infer bioactivity signatures for chemical compounds, enhancing drug discovery by predicting bioactivity for uncharacterized molecules.",
    "summary": "The study introduces a collection of deep neural networks designed to infer bioactivity descriptors for chemical compounds, even those with little or no experimental data. These bioactivity descriptors, or signatures, cover 25 different types, including target profiles, cellular responses, and clinical outcomes. The inferred signatures can replace traditional chemical descriptors in chemoinformatics tasks, offering a biological perspective in navigating chemical space and enriching chemical libraries for activity against specific targets, such as Snail1. The authors implemented signature-activity relationship models, which demonstrated improved prediction performance over traditional chemistry-based classifiers across various benchmarks in biophysical and physiological activity predictions. This approach extends the applicability of bioactivity data to a broader range of chemical compounds, facilitating more efficient exploration and exploitation of the chemical space in drug discovery.",
    "relevance_to_biomedical_research": "The publication is relevant to biomedicine and drug discovery as it presents a method to predict the bioactivity of chemical compounds, which is crucial for identifying biologically relevant chemical space. By enabling the prediction of bioactivity for uncharacterized molecules, this research aids in drug discovery efforts, particularly in the early stages of target identification and hit discovery. The study's application to the drug-orphan target Snail1 highlights its potential impact on identifying new therapeutic agents for challenging targets.",
    "computational_methods": "The computational approach involves using deep neural networks, specifically Siamese Neural Networks (SNNs), to infer bioactivity signatures for chemical compounds. These networks are trained on triplets of molecules to learn embeddings that reflect biological similarities. The input to the networks consists of concatenated chemical signatures, and the output is 128-dimensional bioactivity signatures. The training involved a dataset of 107 molecule triplets, and the networks were validated using various accuracy metrics. The inferred signatures were evaluated for reliability using applicability scores. The models improved prediction accuracy over traditional chemical descriptors in various benchmark tasks, demonstrating the added value of incorporating bioactivity data.",
    "biomedical_keywords": [
        "Drug discovery",
        "Bioactivity prediction",
        "Chemical space"
    ],
    "computational_keywords": [
        "Deep neural networks",
        "Bioactivity signatures",
        "Siamese Neural Networks"
    ],
    "strengths": "The publication's main strength lies in its ability to predict bioactivity for uncharacterized compounds, significantly expanding the chemical space accessible for drug discovery. The use of deep neural networks provides a robust and flexible framework for integrating various types of bioactivity data. The methodology enhances the predictive power of bioactivity models, outperforming traditional chemistry-based classifiers. The study demonstrates practical applications in drug discovery, such as identifying compounds active against the Snail1 target.",
    "limitations": "One limitation is the potential difficulty in interpreting the detailed biological meaning of the 128-dimensional signatures, as they do not directly map to specific biological activities. The method's accuracy depends on the quality and coverage of the training data, which may limit its applicability to compounds with limited bioactivity information. The approach also requires computational resources for training the deep neural networks, which might be a barrier for some users. The inferred signatures' reliability varies depending on the compound, necessitating careful consideration of the applicability scores.",
    "overall_relevance": "The publication has high relevance due to its innovative approach to predicting bioactivity for uncharacterized chemical compounds, which addresses a significant bottleneck in drug discovery. The use of advanced machine learning techniques, such as deep neural networks, reflects a cutting-edge trend in computational drug discovery methods. Published in a high-impact journal, Nature Communications, the study contributes valuable insights into the integration of bioactivity data into chemoinformatics, potentially influencing future research and development in the field."
}